Is a complete SLN research report available?

No complete published report is available for Silence Therapeutics plc (SLN) on this page. Market-directory data, when present, is not a substitute for a reviewed stock analysis.

Silence Therapeutics plc (SLN)

NASDAQ: SLN · USD

$11.6

+0.07 (+0.6%)· Recorded snapshot

Coverage state: Market snapshot only — no published research

Market snapshot recorded 2026-07-31 02:00 UTC. No published research is attached to this ticker. Prices and fundamentals on this server-rendered page are dated snapshots, not a real-time trading feed.

On-demand research

Generate the first SLN analysis

Start the full research workflow when this ticker is ready in our data system.

Market cap	548.9M
Revenue (ttm)	839K
Net income (ttm)	-75M
EPS (ttm)	-$1.59
Shares out	47.2M
Volume	769,513
Beta	1.38
Price target	$29.2	+151.0%

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 839K
Net income (ttm): -75M
EPS (ttm): -$1.59
Market cap: 548.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ALNY	Alnylam Pharmaceuticals, Inc.	27.4B	36.9x	5.7x	96.6%	+47.5%	-37.8%	Strong Buy
ARGX	argenx SE	53.8B	31.3x	10.1x	50.6%	+58.8%	+45.7%	Strong Buy
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Hold

All SLN indicators

Market & fundamental data

Available fields

210

Groups with data

Currency

USD

Showing 210 of 210 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001479615
Company name	Silence Therapeutics plc
Country	United Kingdom
Country code	US
Cusip	82686Q101
Employees	88
Employees Change	-28%
Employees Change Percent	-24.14
Enterprise value	$478.9M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
Isin	US82686Q1013
Last refreshed	2026-07-31
Market cap	$548.9M
Market cap category	Small-Cap
Price	$11.62
Price currency	USD
Rev Per Employee	9,534.09x
Sector	Healthcare
Sector PE	45.51
Sector PE Fwd	24.23
Sic	2834
Symbol	SLN
Website	https://www.silence-therapeutics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-13.67%
EV Sales Forward	93.01x
EV/Sales	570.82x
FCF yield	-11.95%
P/B ratio	11.11x
P/S ratio	654.18x
PS Forward	106.6x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-9,431.27%
EBITDA Margin	-9,431.27%
Gross margin	79.5%
Gross Profit	$667,000
Gross Profit Growth	-96.42%
Gross Profit Growth Q	367.05%
Gross Profit Growth3 Y	-62.24%
Gross Profit Growth5 Y	-29.35%
Net Income	$-75M
Net Income Growth Quarters	1%
Net Income Growth Years	0%
Pretax Margin	-8,942.55%
Profit Per Employee	$-852,716
ROA	-29.79
Roa5y	-26.78
ROCE	-76.49
ROE	-92.56
Roe5y	-218.6
ROIC	-55.14

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	87.42%
Cagr3y	28.29%
Cagr5y	-14.05%
EPS Growth Quarters	1
EPS Growth Years	0
Revenue Growth	-96.97x
Revenue Growth Q	197.18x
Revenue Growth Quarters	1x
Revenue Growth Years	0x
Revenue Growth3 Y	-69.17x
Revenue Growth5 Y	-40.33x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.01
Assets	$115.1M
Cash	$70.1M
Current Assets	$102.9M
Current Liabilities	$10.5M
Debt	$136,000
Debt Equity	$0
Equity	$49.4M
Liabilities	$65.7M
Long Term Assets	$12.3M
Long Term Liabilities	$55.3M
Net Cash	$69.9M
Net Cash By Market Cap	$12.74
Net Cash Growth	-48.75%
Net Debt Equity	$-1.42
Tangible Book Value	$38.8M
Tangible Book Value Per Share	$0.82
WACC	11.83

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	9.83
Net Working Capital	$22.4M
Quick ratio	8.82
Working Capital	$92.4M
Working Capital Turnover	$0.01

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-0.35%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	87.34%
200-day SMA	6.82
3Y total return	111.18%
50-day SMA	8.66
50-day SMA vs 200-day SMA	50over200
5Y total return	-53.09%
All Time High	35
All Time High Change	-66.81%
All Time High Date	2021-05-28
All Time Low	1.97
All Time Low Change	489.59%
All Time Low Date	2025-04-10
ATR	0.87
Beta	1.38
Beta1y	1.11
Beta2y	1.17
Ch YTD	91.04
High	11.77
High52	12.19
High52 Date	2026-07-27
High52ch	-4.68%
Low	10.97
Low52	4.19
Low52 Date	2026-02-12
Low52ch	177.33%
Ma50ch	34.14%
Premarket Change Percent	0.91
Premarket Price	$11.65
Premarket Volume	1,727
Price vs 200-day SMA	70.23%
RSI	62.73
RSI Monthly	57.27
RSI Weekly	69.03
Sharpe ratio	1.12x
Sortino ratio	1.95
Total Return	-0.35%
Tr YTD	91.04
Tr1m	7.65%
Tr1w	1.44%
Tr3m	63.36%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	7
Analyst Count Top	3
Analyst Price Target Top	$75
Analyst Ratings	Buy
Analyst Ratings Top	Strong Buy
Earnings EPS Estimate	$-0.15
Earnings Revenue Estimate	1,322,968x
Earnings Revenue Estimate Growth	490.61x
Operating Income	$-71.6M
Operating margin	-8,534.7
Price target	$29.17
Price Target Change	$151
Price Target Change Top	$545

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	27,461,013%
Float Percent	58.14%
Shares Insiders	29.28%
Shares Institutions	31.23%
Shares Out	47,233,949
Shares Qo Q	0%
Shares Yo Y	0.35%
Short Ratio	2.47
Short Shares	4.41

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-72.6M
Adjusted OCF	-72,546,000
Average Volume	528,020.7x
Bv Per Share	1.05
CAPEX	$-51,000
Ch1m	7.65
Ch1w	1.44
Ch1y	87.34
Ch3m	63.36
Ch3y	111.2
Ch5y	-53.09
Ch6m	134.2
Change	0.61%
Change From Open	0.52
Close	11.55
Days Gap	0.09
Depreciation Amortization	523,000
Dollar Volume	8,941,741.1
Earnings Date	2026-08-05
Earnings Time	bmo
EBIT	$-80.1M
EBITDA	$-80.1M
EPS	$-1.59
F Score	3
FCF	$-65.6M
FCF EV Yield	-13.7x
FCF Per Share	$-1.39
Financing CF	1,000
Fiscal Year End	December
Founded	1,994
Goodwill	10,358,000
Income Tax	$11,000
Investing CF	6,389,000
Is Primary Listing	0
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-03-05
Ma150	6.89
Ma150ch	68.65%
Ma20	10.67
Ma20ch	8.88%
Net CF	-59,229,000
Next Earnings Date	2026-08-10
Open	11.56
Optionable	Yes
Position In Range	81.25
Ppne	1,538,000
Pre Close	11.55
Price Date	2026-07-30
Ptbv Ratio	14.15
Relative Volume	1.46x
Revenue	839,000x
SBC By Revenue	832.06x
Share Based Comp	6,981,000
Tax By Revenue	1.31x
Tr6m	134.17%
Volume	769,513
Z Score	-5.76

Silence Therapeutics plc (SLN)

Coverage state: Market snapshot only — no published research

Generate the first SLN analysis

Price

Financial snapshot

Fair-value bridge

Analyst consensus

Latest news · SLN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All SLN indicators

Profile and market data

Valuation

Profitability

Growth

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Analyst estimates

Ownership and float

Other indicators

Deeper analysis on SLN

Frequently asked questions